ES2339935T3 - Nuevas sales de atorvastatina y composiciones farmaceuticas que las contienen. - Google Patents

Nuevas sales de atorvastatina y composiciones farmaceuticas que las contienen. Download PDF

Info

Publication number
ES2339935T3
ES2339935T3 ES03730380T ES03730380T ES2339935T3 ES 2339935 T3 ES2339935 T3 ES 2339935T3 ES 03730380 T ES03730380 T ES 03730380T ES 03730380 T ES03730380 T ES 03730380T ES 2339935 T3 ES2339935 T3 ES 2339935T3
Authority
ES
Spain
Prior art keywords
atorvastatin
lysine
salt
modification
bands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03730380T
Other languages
English (en)
Spanish (es)
Inventor
Janos Fischer
Krisztina Vukics
Peter Erdelyi
Bela Hegedus
Karoly Tihanyi
Monika Vastag
Sandor Levai
Sandorne Balint
Krisztina Lanczos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Application granted granted Critical
Publication of ES2339935T3 publication Critical patent/ES2339935T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES03730380T 2002-03-28 2003-03-27 Nuevas sales de atorvastatina y composiciones farmaceuticas que las contienen. Expired - Lifetime ES2339935T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0201083A HUP0201083A2 (hu) 2002-03-28 2002-03-28 Új atorvastatinsók és az azokat tartalmazó gyógyszerkészítmények
HU0201083 2002-03-28

Publications (1)

Publication Number Publication Date
ES2339935T3 true ES2339935T3 (es) 2010-05-27

Family

ID=89980299

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03730380T Expired - Lifetime ES2339935T3 (es) 2002-03-28 2003-03-27 Nuevas sales de atorvastatina y composiciones farmaceuticas que las contienen.

Country Status (11)

Country Link
EP (1) EP1490333B1 (https=)
AT (1) ATE455761T1 (https=)
AU (1) AU2003241060A1 (https=)
CY (1) CY1109882T1 (https=)
DE (1) DE60331051D1 (https=)
DK (1) DK1490333T3 (https=)
ES (1) ES2339935T3 (https=)
HU (1) HUP0201083A2 (https=)
PT (1) PT1490333E (https=)
SI (1) SI1490333T1 (https=)
WO (1) WO2003082816A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227041B1 (en) * 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
US20040242673A1 (en) 2003-05-16 2004-12-02 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
JP2007517028A (ja) * 2003-12-29 2007-06-28 レツク・フアーマシユーテイカルズ・デー・デー 非晶質の（４ｒ−シス）−６−［２−［３−フェニル−４−（フェニルカルバモイル）−２−（４−フルオロフェニル）−５−（１−メチルエチル）−ピロール−１−イル］−エチル］−２，２−ジメチル−［１，３］−ジオキサン−４−イル−酢酸を調製する方法
FR2869539B1 (fr) * 2004-04-29 2008-08-08 Univ Paris Descartes Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose
US7875731B2 (en) * 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
EP1814541A4 (en) * 2004-11-22 2009-10-28 Dexcel Pharma Technologies Ltd STABLE ATORVASTATIN FORMULATIONS
CA2613875C (en) * 2005-07-04 2018-09-25 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
TW200745026A (en) 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
WO2011089559A1 (en) * 2010-01-22 2011-07-28 Orchid Chemicals And Pharmaceuticals Limited A novel polymorphic form of atorvastatin salts
MX2010011006A (es) * 2010-10-06 2012-04-18 Senosiain S A De C V Lab Nueva sal de un derivado de pirimidina.
CN103274985B (zh) * 2010-12-03 2016-03-09 上海科州药物研发有限公司 一种阿托伐他汀氨基酸盐
US9717707B2 (en) 2011-12-08 2017-08-01 Hexal Ag Pharmaceutical statin composition
CN103232398B (zh) * 2012-04-28 2016-04-06 上海科州药物研发有限公司 一种瑞舒伐他汀氨基酸盐及其制备方法和应用
WO2014139469A1 (en) * 2013-03-15 2014-09-18 Wuhan Qr Science And Technology Development Co. Ornithine- or aspartate-containing compositions and the uses thereof
CN105246472B (zh) * 2013-03-15 2018-10-12 武汉朗来科技发展有限公司 含有鸟氨酸和/或门冬氨酸的组合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100389518B1 (ko) * 1995-07-17 2003-11-15 워너-램버트 캄파니 엘엘씨 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴)
EP1274401B2 (en) * 2000-04-10 2014-08-13 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids

Also Published As

Publication number Publication date
DE60331051D1 (de) 2010-03-11
HU0201083D0 (https=) 2002-05-29
WO2003082816A1 (en) 2003-10-09
PT1490333E (pt) 2010-03-04
HUP0201083A2 (hu) 2004-06-28
EP1490333B1 (en) 2010-01-20
CY1109882T1 (el) 2014-09-10
AU2003241060A1 (en) 2003-10-13
DK1490333T3 (da) 2010-05-25
SI1490333T1 (sl) 2010-04-30
EP1490333A1 (en) 2004-12-29
ATE455761T1 (de) 2010-02-15

Similar Documents

Publication Publication Date Title
ES2339935T3 (es) Nuevas sales de atorvastatina y composiciones farmaceuticas que las contienen.
US12221417B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
JP4282092B2 (ja) 多形性化合物
ES2562843T3 (es) Forma IV de clorhidrato de ivabradina
ES2384968T3 (es) Monoetanosulfonato de 3-Z-[1-(4-(N-((4-metil-piperazin-1-il)-metilcarbonil)-N-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona y su utilización como composición farmacéutica
ES2217580T3 (es) Composiciones orales de levosimendan.
HUP0300731A2 (hu) Valzartan-sók, eljárás elżállításukra és az azokat tartalmazó gyógyszerkészítmények
JP2021523918A (ja) Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態
US20040220213A1 (en) Zolpidem hemitartrate
RU2662805C2 (ru) Соли дасатиниба в кристаллической форме
CN110283131A (zh) 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法
EP2601176A1 (en) Novel salts of saxagrliptin with organic di-acids
RU2088584C1 (ru) Кристаллический полугидрат 4-(5,6,7,8-тетрагидроимидазо [1,5-а]пиридин-5-ил)-бензонитрил-гидрохлорида
LT3548B (en) Novel esters, method for the preparation thereof and pharmaceutical composition
CZ295472B6 (cs) Eletriptan hydrobromid monohydrát, způsoby jeho přípravy a použití, farmaceutická kompozice s jeho obsahem a způsob přípravy bezvodého eletriptan hydrobromidu
US8946441B2 (en) Polymorphs of an active pharmaceutical ingredient
KR100878140B1 (ko) 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
EP2649996A1 (en) Crystalline forms of sartans like telmisartan with beta blockers
US20090099370A1 (en) Crystalline Form of Perindopril Erbumine
WO2025137731A1 (en) Improved process for making lisdexamfetamine dimesylate
EP1473036B1 (en) Zolpidem hemitartrate solvate
CN106554377B (zh) 吗啡衍生物晶型iii及其制备方法和用途
SK7362002A3 (en) Solid pharmaceutical preparation
HRP20000665A2 (en) CRYSTALLINE FORMS OF 1S-[1<F128M>a<F255D>(2S*,3R*), 9<F128M>a<F255D>]10-DIOXO-N-(2-ETHOXY-5-OXO-TETRAHYDRO-3-FURANYL)-9-[[(1-ISOQUINOLYL)CARBONYL]-AMINO]OCTAHYDRO-6H-PIRIDAZINO[1,2-A][1,2]DIAZEPIN- 1-CARBOXAMIDE
BR112016003169B1 (pt) Polimorfo cristalino de forma 2, composição farmacêutica, uso do polimorfo cristalino de forma 2 e método para a preparação do polimorfo cristalino de forma 2